ArticleJournal of clinical medicine2020
A New Risk Variant for Multiple Sclerosis at 11q23.3
Open access · goldAbstract read
In one paragraph
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Internal m7G methylation: A novel epitranscriptomic contributor in brain development and diseases.Molecular therapy. Nucleic acids · 2023Review
- Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis.Human molecular genetics · 2022Article
- Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 12 institutions in 2 countries.
Elia Gil-VareaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Maria FedetzDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.
Herena EixarchServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Nino SpataroGenetics Laboratory, UDIAT-Centre Diagnòstic. Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
Luisa María VillarDepartments of Immunology and Neurology, Multiple Sclerosis Unit, Hospital Ramon y Cajal, (IRYCIS), 28034 Madrid, Spain.
Elena UrcelayLab. of Genetics of Complex Diseases, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
Albert SaizServicio de Neurología, Hospital Clinic and Institut d'Investigació Biomèdica Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.
Óscar FernándezUnidad de Gestión Clínica de Neurociencias. Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga. Universidad de Málaga, 29010 Málaga, Spain.
Laura LeyvaUnidad de Gestión Clínica de Neurociencias. Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga. Universidad de Málaga, 29010 Málaga, Spain.
Lluís Ramió-TorrentàGirona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital. Neurodegeneration and Neuroinflammation Group, Girona Biomedical Research Institute (IdIBGi). Department of Medical Sciences, Faculty of Medicine, University of Girona, 17190 Girona, Spain.
Koen VandenbroeckInflammation & Biomarkers Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-6967-6485
David OtaeguiNeurosciences Area, Biodonostia Health Research Institute, 20014 San Sebastián, Spain.ORCID 0000-0002-6625-5976
Tamara Castillo-TriviñoServicio de Neurología, Hospital Universitario Donostia, 20014 San Sebastián, Spain.
Guillermo IzquierdoDepartamento de Neurología, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain.
Sunny MalhotraServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Elena BoschInstitute of Evolutionary Biology (CSIC-UPF), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Arcadi NavarroInstitute of Evolutionary Biology (CSIC-UPF), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Antonio AlcinaDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.
Xavier MontalbanServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Fuencisla MatesanzDepartment of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas (IPBLN-CSIC) 18016 Granada, Spain.
Manuel ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat). Institut de Recerca Vall d'Hebron (VHIR). Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-9429-1819
Universitat Autònoma de Barcelona · ESConsejo Superior de Investigaciones Científicas · ESBiogipuzkoa Health Research Institute · ESHospital Regional Universitario de Málaga · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Universitario Virgen Macarena · ESIkerbasque · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESUniversitat de Girona · ESUniversitat Pompeu Fabra · ES
Funding
AEI/FEDER BFU2016-77961-PInstituto de Salud Carlos III PI12/02229, PI15/00587, PI16/01259ISCIII-SGEFI/FEDER PT13/0001MINECO MDM-2014-0370Ministerio de Economía, Industria y Competitividad SAF2016-80595-C2-1-PRed Española de Esclerosis Múltiple RD16/0015/0004, RD16/0015/0002; RD16/0015/0016
Abstract
Genome-wide association studies and meta-analysis have contributed to the identification of more than 200
Indexed as
CXCR5geneticsgenotypingmultiple sclerosissingle nucleotide polymorphismstargeted DNA sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.